Keeping patients out of care facilities--- clozapine rescues Parkinson's patients with troublesome psychosis unresponsive to quetiapine and pimavanserin

被引：0

|

作者：

Iseringhausen, J.

Riboldi, G.

Astudillo, K.

Frucht, S.

机构：

来源：

MOVEMENT DISORDERS | 2023年 / 38卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

1909

引用

收藏

页码：S837 / S837

页数：1

相关论文

共 50 条

[41] Study Outcomes Among Patients with Parkinson's Disease Treated for Psychosis Residing in the Long-Term Care Setting and Newly Initiating Pimavanserin or Off-Label Atypical Antipsychotics
Meyers, Juliana
Nham, Tram
Wang, Stanley
Esterberg, Lizzi
Rashid, Nazia
CNS SPECTRUMS, 2023, 28 (02) : 253 - 253
[42] Risk of agranulocytosis and neutropenia in patients with Parkinson's disease psychosis receiving clozapine treatment: A systematic review and meta-analysis
Limveeraprajak, Nahathai
Makkapavee, Worawut
Likhitsathian, Surinporn
Srisurapanont, Manit
GENERAL HOSPITAL PSYCHIATRY, 2025, 92 : 4 - 11
[43] Improved nighttime sleep and increased daytime wakefulness in patients with Parkinson's disease psychosis treated with pimavanserin, a selective 5-HT2A antagonist
Mills, R.
Bahr, D.
Chi-Burris, K.
Williams, H.
MOVEMENT DISORDERS, 2013, 28 : S225 - S225
[44] Antipsychotic efficacy and motor tolerability in a phase III placebo-controlled study of pimavanserin in patients with Parkinson's disease psychosis (ACP-103-020)
Cummings, J.
Isaacson, S.
Mills, R.
Williams, H.
Chi-Burris, K.
Bahr, D.
Dhall, R.
Ballard, C.
MOVEMENT DISORDERS, 2013, 28 : S170 - S170
[45] Antipsychotic efficacy and motor tolerability in a Phase III placebo-controlled study of pimavanserin in patients with Parkinson's disease psychosis (ACP-103-020)
Cummings, Jeffrey
Isaacson, Stuart
Mills, Roger
Williams, Hilde
Chi-Burris, Kathy
Bahr, Daun
Dhall, Rohit
Ballard, Clive
NEUROLOGY, 2013, 80 (19) : E201 - E202
[46] The effects of treatment with pimavanserin on activities of daily living in patients with Parkinson's disease psychosis: a 16-week, single-arm, open-label study
Evidente, Virgilio G. H.
DeKarske, Daryl
Coate, Bruce
Abler, Victor
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2024, 17
[47] Analysis of Medicare Patients Treated with Pimavanserin versus Other Atypical Antipsychotics: A Cost-Offset Model Evaluating Skilled Nursing Facility Stays and Long-Term Care Admissions in Parkinson's Disease Psychosis
Rajagopalan, Krithika
Rashid, Nazia
Yakkala, Vinod
Doshi, Dilesh
CLINICOECONOMICS AND OUTCOMES RESEARCH, 2024, 16 : 149 - 159
[48] Health care resource utilization patterns among patients with Parkinson's disease psychosis: analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics (vol 26,Pg 34-42,2023)
Rajagopalan, Krithika
Rashid, Nazia
Kumar, Shikhar
Doshi, Dilesh
JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 266 - 266
[49] Efficacy and safety of clozapine and olanzapine:: an open-label study comparing two groups of Parkinson's disease patients with dopaminergic-induced psychosis
Giménez-Roldán, S
Mateo, D
Navarro, E
Ginés, MM
PARKINSONISM & RELATED DISORDERS, 2001, 7 (02) : 121 - 127
[50] Falls Related to Accidental Deactivation of Deep Brain Stimulators in Patients With Parkinson's Disease Living in Long Term Care Facilities
Tousi, Babak
Wilson, Kathy
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2013, 14 (01) : 58 - 59

← 1 2 3 4 5 →